Notice of Extra Ordinary Genral Meeting in Biovitrum AB (publ), 4 December 2009

The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.



In accordance with the listing agreement with NASDAQ OMX Stockholm
AB, Biovitrum AB (publ) hereby announces, also by issuing a press
release, the content of the notice concerning Biovitrum's Extra
Ordinary  General Meeting on 4 December 2009, and the complete
proposal from the Board of Directors regarding the proposal for a
resolution to approve the acquisition of Swedish Orphan International
Holding AB, proposal for a resolution to amend the articles of
association, resolution on a new issue of common shares with
preferential rights for the shareholders subject to the approval of
the General Meeting, proposal for a resolution to amend the articles
of association and proposal for a resolution to authorise the board
of directors to resolve to issue common shares and convertible
participating certificates against payment in kind or by way of
set-off.

Attachments:
- Notice of Biovitrum's Extra Ordinary General Meeting, 4 December
2009

For more information please contact:
Martin Nicklasson, CEO Biovitrum
Phone: +46 8 697 20 00

Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42

Erik Kinnman, EVP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. Biovitrum has revenues of approximately SEK 1.2
billion and approximately 400 employees (prior to the Transaction).
Biovitrum's head office is located in Sweden and the share is listed
on the NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com.

IMPORTANT NOTICE:
The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.
The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of the securities referred to herein in any jurisdiction in
which such offer, solicitation or sale would require preparation of
further prospectuses or other offer documentation, or be unlawful
prior to registration, exemption from registration or qualification
under the securities laws of any such jurisdiction.
The information in this press release does not constitute or form a
part of any offer or solicitation to purchase or subscribe for
securities in the United States. The securities mentioned herein have
not been, and will not be, registered under the United States
Securities Act of 1933 (the "Securities Act"). The securities
mentioned herein may not be offered or sold in the United States
absent

registration or an exemption from the registration requirements of
the Securities Act. There will be no public offer of securities in
the United States.
The information in this press release may not be forwarded or
distributed to any other person and may not be reproduced in any
manner whatsoever. Any forwarding, distribution, reproduction, or
disclosure of this information in whole or in part is unauthorized.
Failure to comply with this directive may result in a violation of
the Securities Act or the applicable laws of other jurisdictions
The above information has been made public in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act.
The information was published at 11:45 CET on November 6, 2009.